

## Catalog #10-2479 Topotecan HCI

CAS# 119413-54-6

10-[(Dimethylamino)methyl]-4S-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, HCl; NSC 609669; SKF-104864A

Lot # R101452

Water-soluble and orally active analog of camptothecin, a DNA topoisomerase I inhibitor. Inhibits topoisomerase I in human MCF-7 breast and DU-145 prostate cancer cells,  $IC_{50}s = 13$  and 2 nM respectively. Downregulates B-Myb and MycN expression in neuroblastoma cells. A clinically useful anticancer agent.

- 1) Schellens et al. (1996), Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor; Br. J. Cancer **73** 1268
- 2) Caceres et al. (2003), Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors; Anticancer Drugs **14** 569
- 3) Sottile et al. (2012), A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma; Oncotarget **3** 535

## **PHYSICAL DATA**

Molecular Weight: 457.91

NMR: (Conforms)

Solubility: DMSO (50 mg/mL); water (50 mg/mL)

Physical Description: Yellow solid

Storage and Stability: Store as supplied at -20°C for up to 2 years from the date of purchase. Solutions in

DMSO or water may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462 <u>www.focusbiomolecules.com</u>